Redhill Biopharma (Redhill Biopharma) YoY EBITDA Growth : 117.64% (As of Jun. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Redhill Biopharma YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Redhill Biopharma's YoY EBITDA Growth for the quarter that ended in Jun. 2023 was 117.64%.

Redhill Biopharma's EBITDA per Share for the three months ended in Jun. 2023 was $0.69.

Redhill Biopharma YoY EBITDA Growth Historical Data

The historical data trend for Redhill Biopharma's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Redhill Biopharma YoY EBITDA Growth Chart

Redhill Biopharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

YoY EBITDA Growth

Get a 7-Day Free Trial

18.14

-10.02

10.20

73.44

128.21

Redhill Biopharma Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Dec23
YoY EBITDA Growth	Get a 7-Day Free Trial															91.10	97.92	492.01	117.64	100.00

Redhill Biopharma YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Redhill Biopharma's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

	YoY EBITDA Growth (A: Dec. 2023 )
=	(EBITDA per Share (A: Dec. 2023 )	-	EBITDA per Share (A: Dec. 2022 ))	/	\| EBITDA per Share (A: Dec. 2022 ) \|
=	(4.061	-	-14.395)	/	\| -14.395 \|
=	128.21 %

Redhill Biopharma's YoY EBITDA Growth for the quarter that ended in Jun. 2023 is calculated as:

	YoY EBITDA Growth (Q: Jun. 2023 )
=	(EBITDA per Share (Q: Jun. 2023 )	-	EBITDA per Share (Q: Jun. 2022 ))	/	\| EBITDA per Share (Q: Jun. 2022 )) \|
=	(0.693	-	-3.928)	/	\| -3.928 \|
=	117.64 %

Redhill Biopharma YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Redhill Biopharma's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Redhill Biopharma (Redhill Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Redhill Biopharma Ltd (NAS:RDHL) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

2RH0:Germany 2RH0:Germany

Address

21 Ha’arba’a Street, Tel Aviv, ISR, 6473921

Website

https://www.redhillbio.com

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.